Jean Reuter

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader, Maude Bouscambert‐Duchamp, Maya Hites et al. · The Lancet Infectious Diseases · 2021 · 338 citations · Full text

Six-Month Outcome of Immunocompromised Patients with Severe Acute Respiratory Distress Syndrome Rescued by Extracorporeal Membrane Oxygenation. An International Multicenter Retrospective Study

Matthieu Schmidt, Peter Schellongowski, Nicolò Patroniti et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 130 citations · Full text

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Florence Ader, Nathan Peiffer‐Smadja, Julien Poissy et al. · Clinical Microbiology and Infection · 2021 · 102 citations · Full text

Clinical Infectious Disease, Open-label Randomized, Antiviral Drug Development +6

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

Marius Trøseid, José Ramón Arribas, Lambert Assoumou et al. · Critical Care · 2023 · 46 citations · Full text

Factors associated with major adverse kidney events in patients who underwent veno-arterial extracorporeal membrane oxygenation

Camille Vinclair, Étienne de Montmollin, Romain Sonneville et al. · Annals of Intensive Care · 2020 · 33 citations · Full text